KR20200063147A - Pdl1 표적화 항체 및 이의 사용 방법 - Google Patents

Pdl1 표적화 항체 및 이의 사용 방법 Download PDF

Info

Publication number
KR20200063147A
KR20200063147A KR1020207008775A KR20207008775A KR20200063147A KR 20200063147 A KR20200063147 A KR 20200063147A KR 1020207008775 A KR1020207008775 A KR 1020207008775A KR 20207008775 A KR20207008775 A KR 20207008775A KR 20200063147 A KR20200063147 A KR 20200063147A
Authority
KR
South Korea
Prior art keywords
antibody
seq
pdl1
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020207008775A
Other languages
English (en)
Korean (ko)
Inventor
테 군데
마티아스 브록
크리스티안 헤스
알렉산더 시모낭
Original Assignee
누맙 세러퓨틱스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP17195781.4A external-priority patent/EP3470429A1/en
Application filed by 누맙 세러퓨틱스 아게 filed Critical 누맙 세러퓨틱스 아게
Priority to KR1020257012651A priority Critical patent/KR20250057935A/ko
Publication of KR20200063147A publication Critical patent/KR20200063147A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
  • Liquid Crystal Substances (AREA)
KR1020207008775A 2017-10-10 2018-10-09 Pdl1 표적화 항체 및 이의 사용 방법 Ceased KR20200063147A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020257012651A KR20250057935A (ko) 2017-10-10 2018-10-09 Pdl1 표적화 항체 및 이의 사용 방법

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP17195781.4 2017-10-10
EP17195781.4A EP3470429A1 (en) 2017-10-10 2017-10-10 Antibodies targeting pdl1 and methods of use thereof
EP18167094.4 2018-04-12
EP18167094 2018-04-12
EP18180816 2018-06-29
EP18180816.3 2018-06-29
PCT/EP2018/077511 WO2019072869A1 (en) 2017-10-10 2018-10-09 PDL1 TARGETING ANTIBODIES AND METHODS OF USE THEREOF

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020257012651A Division KR20250057935A (ko) 2017-10-10 2018-10-09 Pdl1 표적화 항체 및 이의 사용 방법

Publications (1)

Publication Number Publication Date
KR20200063147A true KR20200063147A (ko) 2020-06-04

Family

ID=63834022

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020207008775A Ceased KR20200063147A (ko) 2017-10-10 2018-10-09 Pdl1 표적화 항체 및 이의 사용 방법
KR1020257012651A Pending KR20250057935A (ko) 2017-10-10 2018-10-09 Pdl1 표적화 항체 및 이의 사용 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020257012651A Pending KR20250057935A (ko) 2017-10-10 2018-10-09 Pdl1 표적화 항체 및 이의 사용 방법

Country Status (11)

Country Link
US (2) US12077588B2 (https=)
EP (1) EP3694879A1 (https=)
JP (3) JP7791650B2 (https=)
KR (2) KR20200063147A (https=)
CN (2) CN120248120A (https=)
AU (2) AU2018348430B2 (https=)
CA (1) CA3074802A1 (https=)
IL (2) IL273578B2 (https=)
MA (1) MA50353A (https=)
SG (1) SG11202001654TA (https=)
WO (1) WO2019072869A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3015094T3 (en) * 2017-06-05 2025-04-29 Numab Therapeutics AG Anti-hsa antibodies
CN111194323B (zh) * 2017-10-10 2024-07-09 努玛治疗有限公司 多特异性抗体
EP3833691B1 (en) * 2019-04-26 2024-09-25 I-Mab Biopharma Co., Ltd. Human pd-l1 antibodies
EP3816185A1 (en) * 2019-11-04 2021-05-05 Numab Therapeutics AG Multispecific antibody directed against pd-l1 and a tumor-associated antigen
WO2024160721A1 (en) 2023-01-30 2024-08-08 Kymab Limited Antibodies
IL324608A (en) * 2023-05-19 2026-01-01 Numab Therapeutics AG Antibody variable domains and antibodies having decreased immunogenicity
WO2025133389A1 (en) 2023-12-22 2025-06-26 Numab Therapeutics AG Antibody binding domains having specificity for lilrb2

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5013653A (en) 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
ATE243754T1 (de) 1987-05-21 2003-07-15 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
EP1291360A1 (en) 1991-12-13 2003-03-12 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
EP1958962A3 (en) 1997-06-12 2013-05-01 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
DE19819846B4 (de) 1998-05-05 2016-11-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Multivalente Antikörper-Konstrukte
CN1753912B (zh) * 2002-12-23 2011-11-02 惠氏公司 抗pd-1抗体及其用途
NZ628923A (en) 2009-11-24 2016-02-26 Medimmune Ltd Targeted binding agents against b7-h1
HRP20201595T1 (hr) 2011-11-28 2020-12-11 Merck Patent Gmbh Anti-pd-l1 protutijela i njihova uporaba
EP3415534A1 (en) * 2013-05-10 2018-12-19 Numab Therapeutics AG Bispecific constructs and their use in the treatment of various diseases
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
EP3307776A1 (en) 2015-06-15 2018-04-18 Numab Innovation AG Hetero-dimeric multi-specific antibody format
CN106939047B (zh) 2016-01-04 2021-08-31 江苏怀瑜药业有限公司 一种pd-l1抗体及其制备方法
KR20180096789A (ko) * 2016-01-11 2018-08-29 인히브릭스, 인크. 다가 및 다중특이적 41bb-결합 융합 단백질
US11129047B2 (en) * 2017-05-05 2021-09-21 Nokia Technologies Oy Radio link control status reporting

Also Published As

Publication number Publication date
MA50353A (fr) 2020-08-19
WO2019072869A1 (en) 2019-04-18
IL323510A (en) 2025-11-01
CN120248120A (zh) 2025-07-04
AU2025271488A1 (en) 2026-01-08
SG11202001654TA (en) 2020-03-30
KR20250057935A (ko) 2025-04-29
EP3694879A1 (en) 2020-08-19
US12077588B2 (en) 2024-09-03
IL273578A (en) 2020-05-31
IL273578B1 (en) 2025-11-01
JP2025102791A (ja) 2025-07-08
CN111225926B (zh) 2025-03-14
IL273578B2 (en) 2026-03-01
JP2023166403A (ja) 2023-11-21
JP7649825B2 (ja) 2025-03-21
CA3074802A1 (en) 2019-04-18
JP7791650B2 (ja) 2025-12-24
JP2021501569A (ja) 2021-01-21
AU2018348430A1 (en) 2020-03-12
AU2018348430B2 (en) 2025-09-04
US20250066482A1 (en) 2025-02-27
CN111225926A (zh) 2020-06-02
US20200283528A1 (en) 2020-09-10

Similar Documents

Publication Publication Date Title
US12202911B2 (en) Multispecific antibody comprising CD137 binding domain and PDL1 binding domain
KR102907326B1 (ko) Cd137을 표적화하는 항체 및 이의 사용 방법
JP7649825B2 (ja) Ｐｄｌ１を標的とする抗体及びそれを用いる方法
JP2025020172A (ja) Ｃｄ１３７を標的とする抗体およびその使用方法
EP3470429A1 (en) Antibodies targeting pdl1 and methods of use thereof
EP3636320A1 (en) Antibodies targeting cd137 and methods of use thereof
KR102955501B1 (ko) Cd137을 표적화하는 항체 및 이의 사용 방법

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200326

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20211005

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20231027

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20240730

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

AMND Amendment
PX0901 Re-examination

Patent event code: PX09012R01I

Patent event date: 20241202

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20250115

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20250115

X601 Decision of rejection after re-examination